Event JSON
{
"id": "6e1dcb41b1be0aae955029b5b5aabc70008c2103c68f967636b75c3852b6cae7",
"pubkey": "9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"created_at": 1738787334,
"kind": 1,
"tags": [
[
"r",
"https://www.cnbc.com/2025/02/05/novo-nordisk-earnings-ceo-lars-fruergaard-jorgensen-discusses-wegovy.html"
],
[
"subject",
"Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs"
],
[
"published_at",
"1738786510"
],
[
"image",
"https://image.cnbcfm.com/api/v1/image/107378876-1709041957890-gettyimages-1819255240-raa-novonord231203_npsLh.jpeg?v=1716568166\u0026w=1920\u0026h=1080"
],
[
"p",
"9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://image.cnbcfm.com/api/v1/image/107378876-1709041957890-gettyimages-1819255240-raa-novonord231203_npsLh.jpeg?v=1716568166\u0026w=1920\u0026h=1080"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Novo Nordisk's obesity drug Wegovy has been struggling to gain traction, with prescription data suggesting it's losing ground to rival Zepbound from Eli Lilly. Despite this, the company's stock rose 4% after it beat fourth-quarter expectations and provided a sales growth forecast. Novo's CEO, Lars Fruergaard Jorgensen, expressed confidence in the company's ability to supply more starter doses and increase volume. The company also tried to reassure investors about the effectiveness of its experimental drug CagriSema and its earlier-stage treatment amycretin."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqn3qaz9j6wmk602anmwwkvhn8lhfrxgxar2xx5e0lgzn9jdwkvlxqy56fv4\nhttps://image.cnbcfm.com/api/v1/image/107378876-1709041957890-gettyimages-1819255240-raa-novonord231203_npsLh.jpeg?v=1716568166\u0026w=1920\u0026h=1080\nOzempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.\nhttps://www.cnbc.com/2025/02/05/novo-nordisk-earnings-ceo-lars-fruergaard-jorgensen-discusses-wegovy.html",
"sig": "c9a8d865844a4e4ddc3b1f6f492b613effb8839e60cbcf5efdc82fc23e08a593ebc6544603eee4307916c688d369eb20ffe6331ed85b18f7700456a0ab236f6f"
}
